JAC Advance Access published online on March 17, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh156
© 2004 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original article
1 Department of Infection,
GKT School of Medicine, St Thomas’ Hospital Campus, London,
UK;
* Corresponding author. E-mail: anna.king{at}kcl.ac.uk.
Received 5 November 2003
; revised 15 January 2004
; accepted 2 February 2004
Objective: We compared the in
vitro activity of telavancin with that of vancomycin, teicoplanin,
linezolid, quinupristin/dalfopristin, moxifloxacin and ampicillin,
penicillin or oxacillin as appropriate, by the NCCLS/EUCAST and
BSAC methods. Methods: The organisms (n = 401)
included in the study were patient isolates from St Thomas’ Hospital
and were selected to include representatives of the clinically important
Gram-positive aerobic species. Susceptibility testing was performed
by agar dilution methods on Mueller-Hinton agar according
to the NCCLS/EUCAST guidelines, in comparison with Iso-Sensitest
agar according to the BSAC guidelines. Results: Telavancin was active against all the
Gram-positive species tested and nearly 90% of isolates included
in the study had telavancin MICs Conclusion: The susceptibility breakpoints for
telavancin have yet to be established, but it would appear that
telavancin has superior potency to the other tested glycopeptides,
and on a weight-for-weight basis displays activity that is comparable
to, or better than, that of the other agents tested.
Keywords: Staphylococcus aureus, enterococci,
streptococci, glycopeptides, susceptibility testing
Comparative in vitro activity
of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent
anti-infective with multiple mechanisms of action against Gram-positive
bacteria
2 Theravance, Inc., 901 Gateway
Blvd, South San Francisco, CA 94080, USA
1
mg/L. Vancomycin-resistant enterococci and lactobacilli isolates
with vancomycin MICs > 64 mg/L had telavancin MIC ranges
of 0.5-8 and 2-16 mg/L, respectively. There was
no evidence of cross-resistance with other comparator drugs. The
results for telavancin for the two susceptibility testing methods
were mostly either the same or within one doubling dilution.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Kosowska-Shick, C. Clark, G. A. Pankuch, P. McGhee, B. Dewasse, L. Beachel, and P. C. Appelbaum Activity of Telavancin against Staphylococci and Enterococci Determined by MIC and Resistance Selection Studies Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4217 - 4224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. N. Leonard, C. Vidaillac, and M. J. Rybak Activity of Telavancin against Staphylococcus aureus Strains with Various Vancomycin Susceptibilities in an In Vitro Pharmacokinetic/Pharmacodynamic Model with Simulated Endocardial Vegetations Antimicrob. Agents Chemother., July 1, 2009; 53(7): 2928 - 2933. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. O. Darouiche, M. D. Mansouri, and M. J. Schneidkraut Comparative Efficacies of Telavancin and Vancomycin in Preventing Device-Associated Colonization and Infection by Staphylococcus aureus in Rabbits Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2626 - 2628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Charneski, P. N Patel, and D. Sym Telavancin: A Novel Lipoglycopeptide Antibiotic Ann. Pharmacother., May 1, 2009; 43(5): 928 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Yu. Lubenko, E. V. Strukova, M. V. Smirnova, S. N. Vostrov, Y. A. Portnoy, S. H. Zinner, and A. A. Firsov Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model J. Antimicrob. Chemother., November 1, 2008; 62(5): 1065 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. J. Brown, R. Hope, D. M. Livermore, G. Brick, K. Broughton, R. C. George, R. Reynolds, and on behalf of the BSAC Working Parties on Resistanc Non-susceptibility trends among enterococci and non-pneumococcal streptococci from bacteraemias in the UK and Ireland, 2001-06 J. Antimicrob. Chemother., November 1, 2008; 62(suppl_2): ii75 - ii85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Wong, S. L. Barriere, M. M. Kitt, and M. R. Goldberg Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects J. Antimicrob. Chemother., October 1, 2008; 62(4): 780 - 783. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Draghi, B. M. Benton, K. M. Krause, C. Thornsberry, C. Pillar, and D. F. Sahm In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative J. Antimicrob. Chemother., July 1, 2008; 62(1): 116 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Krause, M. Renelli, S. Difuntorum, T. X. Wu, D. V. Debabov, and B. M. Benton In Vitro Activity of Telavancin against Resistant Gram-Positive Bacteria Antimicrob. Agents Chemother., July 1, 2008; 52(7): 2647 - 2652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Draghi, B. M. Benton, K. M. Krause, C. Thornsberry, C. Pillar, and D. F. Sahm Comparative Surveillance Study of Telavancin Activity against Recently Collected Gram-Positive Clinical Isolates from across the United States Antimicrob. Agents Chemother., July 1, 2008; 52(7): 2383 - 2388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Attwood and K. L. LaPlante Telavancin: A novel lipoglycopeptide antimicrobial agent Am. J. Health Syst. Pharm., November 15, 2007; 64(22): 2335 - 2348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. T. M. Jansen, A. Verel, J. Verhoef, and D. Milatovic In Vitro Activity of Telavancin against Gram-Positive Clinical Isolates Recently Obtained in Europe Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3420 - 3424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Miro, C. Garcia-de-la-Maria, Y. Armero, E. de-Lazzari, D. Soy, A. Moreno, A. del Rio, M. Almela, C. A. Mestres, J. M. Gatell, et al. Efficacy of Telavancin in the Treatment of Experimental Endocarditis Due to Glycopeptide-Intermediate Staphylococcus aureus Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2373 - 2377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Barcia-Macay, S. Lemaire, M.-P. Mingeot-Leclercq, P. M. Tulkens, and F. Van Bambeke Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus J. Antimicrob. Chemother., December 1, 2006; 58(6): 1177 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Stryjewski, V. H. Chu, W. D. O'Riordan, B. L. Warren, L. M. Dunbar, D. M. Young, M. Vallee, V. G. Fowler Jr., J. Morganroth, S. L. Barriere, et al. Telavancin versus Standard Therapy for Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: FAST 2 Study Antimicrob. Agents Chemother., March 1, 2006; 50(3): 862 - 867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Stucki, P. Gerber, F. Acosta, M. Cottagnoud, and P. Cottagnoud Efficacy of Telavancin against Penicillin-Resistant Pneumococci and Staphylococcus aureus in a Rabbit Meningitis Model and Determination of Kinetic Parameters Antimicrob. Agents Chemother., February 1, 2006; 50(2): 770 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. K. Sun, K. Duchin, C. H. Nightingale, J.-P. Shaw, J. Seroogy, and D. P. Nicolau Tissue Penetration of Telavancin after Intravenous Administration in Healthy Subjects Antimicrob. Agents Chemother., February 1, 2006; 50(2): 788 - 790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Reyes, R. Skinner, K. Kaniga, K. M. Krause, J. Shelton, G. P. Obedencio, A. Gough, M. Conner, and S. S. Hegde Efficacy of Telavancin (TD-6424), a Rapidly Bactericidal Lipoglycopeptide with Multiple Mechanisms of Action, in a Murine Model of Pneumonia Induced by Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4344 - 4346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. Madrigal, L. Basuino, and H. F. Chambers Efficacy of Telavancin in a Rabbit Model of Aortic Valve Endocarditis Due to Methicillin-Resistant Staphylococcus aureus or Vancomycin-Intermediate Staphylococcus aureus Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3163 - 3165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Higgins, R. Chang, D. V. Debabov, J. Leung, T. Wu, K. M. Krause, E. Sandvik, J. M. Hubbard, K. Kaniga, D. E. Schmidt Jr., et al. Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., March 1, 2005; 49(3): 1127 - 1134. [Abstract] [Full Text] [PDF]
|
|